Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The 'big pharma' dilemma: develop new drugs or promote existing ones?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Trends in resource allocation to SG&Amp;A, R&D and COGS in the pharmaceutical industry: 1975–2007.


  1. Loscalzo, J. The NIH budget and the future of biomedical research. N. Engl. J. Med. 354, 1665–1667 (2006).

    Article  CAS  PubMed  Google Scholar 

  2. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

    Article  PubMed  Google Scholar 

  3. Sewing, A. et al. Helping science to succeed: improving processes in R&D. Drug Discov. Today 13, 227–233 (2008).

    Article  PubMed  Google Scholar 

  4. Gagnon, M. A. & Lexchin, J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5, e1 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Donohue, J.M., Cevasco, M. & Rosenthal, M. B. A decade of direct-to-consumer advertising of prescription drugs. N. Engl. J. Med. 357, 673–681 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Wharton Research Data Services (WRDS) [online], (2009).

  7. Lev, B. Intangibles: Management, Measurement, and Reporting (Brookings Institution Press, Washington D.C., 2001).

    Google Scholar 

  8. Chan, L.K.C., Lakonishok, J. & Sougiannis, T. The stock market valuation of research and development expenditures. J. Finance LVI(6), 2431–2456 (2001).

    Article  Google Scholar 

  9. Bebchuk, L .A. & Fried, J. M. Pay Without Performance (Harvard University Press, Massachusetts, 2006).

    Book  Google Scholar 

  10. Kothari, S.P., Laguerre, T.E. & Leone, A.J. Capitalization versus expensing: evidence on the uncertainty of future earnings from capital expenditures versus R&D outlays. Rev. Account Stud. 7, 355–382 (2002).

    Article  Google Scholar 

  11. Lev, B. & Sougiannis, T. The capitalization, amortization and value-relevance of R&D. J. Account Econ. 21, 107–138 (1996).

    Article  Google Scholar 

  12. Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 116, 2837–2842 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ram Weiss.

Supplementary information

Supplementary information S1 (box)

Basis of analysis (PDF 787 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Weiss, D., Naik, P. & Weiss, R. The 'big pharma' dilemma: develop new drugs or promote existing ones?. Nat Rev Drug Discov 8, 533–534 (2009).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing